Radiofrequency ablation with or without capecitabine maintenance therapy for lung oligometastases from colorectal cancer
No clear guidelines for long-term postoperative maintenance therapy have been established for patients with lung oligometastases from colorectal cancer (CRC) who achieve radiological no evidence of disease after radiofrequency ablation (RFA) treatment. We compared the outcomes of patients with lung...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG Jg. 31; H. 35; S. 110152 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
21.09.2025
|
| Schlagworte: | |
| ISSN: | 2219-2840, 2219-2840 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | No clear guidelines for long-term postoperative maintenance therapy have been established for patients with lung oligometastases from colorectal cancer (CRC) who achieve radiological no evidence of disease after radiofrequency ablation (RFA) treatment. We compared the outcomes of patients with lung oligometastases from CRC after RFA plus maintenance capecitabine with RFA alone.
To determine whether adding capecitabine to RFA improves prognosis compared with RFA alone.
This multicenter retrospective study included consecutive patients from two tertiary cancer centers treated for pulmonary oligometastases from CRC between 2016 and 2023. Subjects were assigned to RFA plus capecitabine (combined) or RFA alone (only RFA) groups. Primary outcomes included overall survival (OS) and progression-free survival (PFS) survival and the secondary outcome was local tumor progression (LTP). The OS, PFS, and LTP rates were compared between the two groups. In addition, prognostic factors were identified using univariate and multivariate analyses.
Combination therapy (RFA + capecitabine,
= 148) and RFA monotherapy (
= 99) were compared in patients with CRC and lung metastases. The median OS was 37.8 months (22.4, 50.3), the PFS was 18.7 months (13.0, 36.5), and the LTP was 31.5 months (20.0, 52.4) in the Only RFA group. The OS increased significantly (
= 0.011) and the LTP decreased at all time points (
< 0.001) in the combined group. The multivariate cox analysis revealed that combined chemotherapy significantly improved OS, with hazard ratios ranging from 0.29 to 0.35 (all
< 0.015) after adjusting for demographic, tumor, and treatment-related factors. The risk of death was consistently lower in the combination therapy group compared to RFA monotherapy.
RFA prolongs survival and local control in patients with CRC pulmonary oligometastases. Adjuvant capecitabine increases OS and reduces LTP compared to RFA alone, but PFS did not significantly change. |
|---|---|
| AbstractList | No clear guidelines for long-term postoperative maintenance therapy have been established for patients with lung oligometastases from colorectal cancer (CRC) who achieve radiological no evidence of disease after radiofrequency ablation (RFA) treatment. We compared the outcomes of patients with lung oligometastases from CRC after RFA plus maintenance capecitabine with RFA alone.BACKGROUNDNo clear guidelines for long-term postoperative maintenance therapy have been established for patients with lung oligometastases from colorectal cancer (CRC) who achieve radiological no evidence of disease after radiofrequency ablation (RFA) treatment. We compared the outcomes of patients with lung oligometastases from CRC after RFA plus maintenance capecitabine with RFA alone.To determine whether adding capecitabine to RFA improves prognosis compared with RFA alone.AIMTo determine whether adding capecitabine to RFA improves prognosis compared with RFA alone.This multicenter retrospective study included consecutive patients from two tertiary cancer centers treated for pulmonary oligometastases from CRC between 2016 and 2023. Subjects were assigned to RFA plus capecitabine (combined) or RFA alone (only RFA) groups. Primary outcomes included overall survival (OS) and progression-free survival (PFS) survival and the secondary outcome was local tumor progression (LTP). The OS, PFS, and LTP rates were compared between the two groups. In addition, prognostic factors were identified using univariate and multivariate analyses.METHODSThis multicenter retrospective study included consecutive patients from two tertiary cancer centers treated for pulmonary oligometastases from CRC between 2016 and 2023. Subjects were assigned to RFA plus capecitabine (combined) or RFA alone (only RFA) groups. Primary outcomes included overall survival (OS) and progression-free survival (PFS) survival and the secondary outcome was local tumor progression (LTP). The OS, PFS, and LTP rates were compared between the two groups. In addition, prognostic factors were identified using univariate and multivariate analyses.Combination therapy (RFA + capecitabine, n = 148) and RFA monotherapy (n = 99) were compared in patients with CRC and lung metastases. The median OS was 37.8 months (22.4, 50.3), the PFS was 18.7 months (13.0, 36.5), and the LTP was 31.5 months (20.0, 52.4) in the Only RFA group. The OS increased significantly (P = 0.011) and the LTP decreased at all time points (P < 0.001) in the combined group. The multivariate cox analysis revealed that combined chemotherapy significantly improved OS, with hazard ratios ranging from 0.29 to 0.35 (all P < 0.015) after adjusting for demographic, tumor, and treatment-related factors. The risk of death was consistently lower in the combination therapy group compared to RFA monotherapy.RESULTSCombination therapy (RFA + capecitabine, n = 148) and RFA monotherapy (n = 99) were compared in patients with CRC and lung metastases. The median OS was 37.8 months (22.4, 50.3), the PFS was 18.7 months (13.0, 36.5), and the LTP was 31.5 months (20.0, 52.4) in the Only RFA group. The OS increased significantly (P = 0.011) and the LTP decreased at all time points (P < 0.001) in the combined group. The multivariate cox analysis revealed that combined chemotherapy significantly improved OS, with hazard ratios ranging from 0.29 to 0.35 (all P < 0.015) after adjusting for demographic, tumor, and treatment-related factors. The risk of death was consistently lower in the combination therapy group compared to RFA monotherapy.RFA prolongs survival and local control in patients with CRC pulmonary oligometastases. Adjuvant capecitabine increases OS and reduces LTP compared to RFA alone, but PFS did not significantly change.CONCLUSIONRFA prolongs survival and local control in patients with CRC pulmonary oligometastases. Adjuvant capecitabine increases OS and reduces LTP compared to RFA alone, but PFS did not significantly change. No clear guidelines for long-term postoperative maintenance therapy have been established for patients with lung oligometastases from colorectal cancer (CRC) who achieve radiological no evidence of disease after radiofrequency ablation (RFA) treatment. We compared the outcomes of patients with lung oligometastases from CRC after RFA plus maintenance capecitabine with RFA alone. To determine whether adding capecitabine to RFA improves prognosis compared with RFA alone. This multicenter retrospective study included consecutive patients from two tertiary cancer centers treated for pulmonary oligometastases from CRC between 2016 and 2023. Subjects were assigned to RFA plus capecitabine (combined) or RFA alone (only RFA) groups. Primary outcomes included overall survival (OS) and progression-free survival (PFS) survival and the secondary outcome was local tumor progression (LTP). The OS, PFS, and LTP rates were compared between the two groups. In addition, prognostic factors were identified using univariate and multivariate analyses. Combination therapy (RFA + capecitabine, = 148) and RFA monotherapy ( = 99) were compared in patients with CRC and lung metastases. The median OS was 37.8 months (22.4, 50.3), the PFS was 18.7 months (13.0, 36.5), and the LTP was 31.5 months (20.0, 52.4) in the Only RFA group. The OS increased significantly ( = 0.011) and the LTP decreased at all time points ( < 0.001) in the combined group. The multivariate cox analysis revealed that combined chemotherapy significantly improved OS, with hazard ratios ranging from 0.29 to 0.35 (all < 0.015) after adjusting for demographic, tumor, and treatment-related factors. The risk of death was consistently lower in the combination therapy group compared to RFA monotherapy. RFA prolongs survival and local control in patients with CRC pulmonary oligometastases. Adjuvant capecitabine increases OS and reduces LTP compared to RFA alone, but PFS did not significantly change. |
| Author | Ying, Lei-Lei Zhao, Qing He, Xin-Hong Xu, Li-Chao Wang, Ying Wang, Yao-Hui Li, Wen-Tao Song, Ge Li, Ke-Ning Chen, Chao Hu, Yu-Bin Huang, Hao-Zhe Yan, Yan Du, Nan |
| Author_xml | – sequence: 1 givenname: Ke-Ning surname: Li fullname: Li, Ke-Ning organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 2 givenname: Lei-Lei surname: Ying fullname: Ying, Lei-Lei organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 3 givenname: Nan surname: Du fullname: Du, Nan organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 4 givenname: Ying surname: Wang fullname: Wang, Ying organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 5 givenname: Hao-Zhe surname: Huang fullname: Huang, Hao-Zhe organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 6 givenname: Yao-Hui surname: Wang fullname: Wang, Yao-Hui organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 7 givenname: Li-Chao surname: Xu fullname: Xu, Li-Chao organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 8 givenname: Qing surname: Zhao fullname: Zhao, Qing organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 9 givenname: Ge surname: Song fullname: Song, Ge organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 10 givenname: Yu-Bin surname: Hu fullname: Hu, Yu-Bin organization: Department of Tumor and Vascular Interventional Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350000, Fujian Province, China – sequence: 11 givenname: Wen-Tao surname: Li fullname: Li, Wen-Tao organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 12 givenname: Yan surname: Yan fullname: Yan, Yan organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 13 givenname: Chao surname: Chen fullname: Chen, Chao organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China – sequence: 14 givenname: Xin-Hong surname: He fullname: He, Xin-Hong email: xinhong.he@shca.org.cn organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. xinhong.he@shca.org.cn |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/41024768$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkFtLw0AQhRdR7EX_gA-yj74k7i1N8ijFGxQE0ecw2UzaLZvdutlY--8NWkEYOAPzzYFzZuTUeYeEXHGWylwVt_vtOv2UPDUySzlnPBMnZCoELxNRKHb6b5-QWd9vGRNSZuKcTBRnQuWLYkq-XqExvg34MaDTBwq1hWi8o3sTN9SHH_VDpBp2qE2E2jikHRgX0YHTSOMGA-wOtB1hO7g19dasfYcR-nGwp23wHdXe-oA6gh2dxrdwQc5asD1eHnVO3h_u35ZPyerl8Xl5t0q0ZCwmmSpBi6bWWDR5URe5kgAFSCY0SsSmVC3koJpmzDNea1XrphRSL1pWspxlYk5ufn13wY8Z-1h1ptdoLTj0Q19JkWUF46XkI3p9RIe6w6baBdNBOFR_bYlv1Nty7Q |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Copyright_xml | – notice: The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.3748/wjg.v31.i35.110152 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 2219-2840 |
| ExternalDocumentID | 41024768 |
| Genre | Multicenter Study Journal Article Comparative Study |
| GroupedDBID | --- 123 29R 2WC 36B 53G 5VR 8WL AAKDD ACGFO AENEX ALMA_UNASSIGNED_HOLDINGS CCEZO CGR CHBEP CIEJG CS3 CUY CVF CW9 DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 HYE NPM OK1 P2P RNS RPM TR2 XSB 7X8 |
| ID | FETCH-LOGICAL-c300t-549ac2dbce8d78b8743aa8a302ce3eed94fa7a4dd247b87b4bcd923c6f0907052 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001583165600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2219-2840 |
| IngestDate | Tue Sep 30 19:07:46 EDT 2025 Sun Nov 16 02:01:21 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 35 |
| Keywords | Radiofrequency ablation Capecitabine Lung oligometastases Maintenance therapy Colorectal cancer |
| Language | English |
| License | The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c300t-549ac2dbce8d78b8743aa8a302ce3eed94fa7a4dd247b87b4bcd923c6f0907052 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doi.org/10.3748/wjg.v31.i35.110152 |
| PMID | 41024768 |
| PQID | 3255801931 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3255801931 pubmed_primary_41024768 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-Sep-21 20250921 |
| PublicationDateYYYYMMDD | 2025-09-21 |
| PublicationDate_xml | – month: 09 year: 2025 text: 2025-Sep-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | World journal of gastroenterology : WJG |
| PublicationTitleAlternate | World J Gastroenterol |
| PublicationYear | 2025 |
| SSID | ssj0023352 |
| Score | 2.4661381 |
| Snippet | No clear guidelines for long-term postoperative maintenance therapy have been established for patients with lung oligometastases from colorectal cancer (CRC)... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 110152 |
| SubjectTerms | Adult Aged Antimetabolites, Antineoplastic - therapeutic use Capecitabine - administration & dosage Capecitabine - therapeutic use Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Colorectal Neoplasms - therapy Combined Modality Therapy - methods Female Humans Lung Neoplasms - mortality Lung Neoplasms - secondary Lung Neoplasms - therapy Maintenance Chemotherapy - methods Male Middle Aged Prognosis Progression-Free Survival Radiofrequency Ablation - adverse effects Radiofrequency Ablation - methods Retrospective Studies Treatment Outcome |
| Title | Radiofrequency ablation with or without capecitabine maintenance therapy for lung oligometastases from colorectal cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/41024768 https://www.proquest.com/docview/3255801931 |
| Volume | 31 |
| WOSCitedRecordID | wos001583165600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA_qPHjxA7_mFxG8dmubtGlPIuLw4hiisFtJk3RUtna23XT_ve-1nZ4EwUt7KIE0ee_l9_I-foTcGJdppW1thYnEkhwZWEECsuwLH9tLMTfksiabEMNhMB6Ho_bCrWzTKtc2sTbUOld4R95ngH3BmobMuZ2_W8gahdHVlkJjk3QYQBlUTDH-jiK4WE-E5HKglRaYYbspmsGGK_2Pt0lvyZxeyjzMhHew8Og3iFkfNYO9_05yn-y2IJPeNVJxQDZMdkg-n6VO86RocqdXVMZNGhzFq1iaF_U7X1QUU6JUWknwmQ2dSWwogV05DG1qtVYUcC6dgpGg-TSd5DNTSYCYpSkp1qpQbIONZhQmoHBYcUReBw8v949Wy7tgKWbblQUuo1SujpUJtAjiAECGlIFktqsMgzM15IkUkmvtcgFfYx4rDThR-YkNrrbtucdkK8szc0rgV0JwYBymYgU4wksCox3uCN8zApEE75Lr9UJGINcYrJCZyRdl9LOUXXLS7EY0bxpwRBxQEQc_6ewPo8_JjouUvRhIci5IJwGtNpdkWy2rtCyuaoGB53D09AVrwc3a |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Radiofrequency+ablation+with+or+without+capecitabine+maintenance+therapy+for+lung+oligometastases+from+colorectal+cancer&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Li%2C+Ke-Ning&rft.au=Ying%2C+Lei-Lei&rft.au=Du%2C+Nan&rft.au=Wang%2C+Ying&rft.date=2025-09-21&rft.eissn=2219-2840&rft.volume=31&rft.issue=35&rft.spage=110152&rft_id=info:doi/10.3748%2Fwjg.v31.i35.110152&rft_id=info%3Apmid%2F41024768&rft_id=info%3Apmid%2F41024768&rft.externalDocID=41024768 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2219-2840&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2219-2840&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2219-2840&client=summon |